ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000624

Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating

Identifieur interne : 000624 ( PascalFrancis/Corpus ); précédent : 000623; suivant : 000625

Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating

Auteurs : W. M. M. Schüpbach ; J.-C. Corvol ; V. Czernecki ; M. B. Djebara ; J.-L. Golmard ; Y. Agid ; A. Hartmann

Source :

Journal of neurology, neurosurgery and psychiatry [ 0022-3050 ] ; 2010.

RBID : Pascal:10-0032960

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Voie abord.

English descriptors

KwdEn :
- Nervous system diseases, Parkinson disease, Surgical approach.

Abstract

Objective: To assess the ability of potentially neuroprotective compounds to slow the progression of Parkinson's disease (PD), sensitive rating scales are needed to detect clinically meaningful effects. The topographical progression of motor signs in early untreated PD was evaluated to complement current clinical ratings and enhance the sensitivity to detect disease progression. Methods: 12 patients referred for diagnostic evaluation of untreated de novo PD underwent detailed clinical assessment of motor parkinsonian signs at baseline and after 6 and 12 months of follow-up using the Unified Parkinson's Disease Rating Scale, motor part (UPDRS-III), and a newly developed approach of detailed segmental rating taking into account the localisation of motor signs in all of the major joints and muscle groups in the body. The progression of PD, as measured with the UPDRS-III, was compared with the segmental ratings. Results: UPDRS-III scores and segmental ratings for rigidity and rest and postural tremor, but not bradykinesia, progressed significantly during the observation period. Progression of normalised segmental ratings for rigidity and tremor was significantly larger than the UPDRS-III ratings over 1 year. The segmental ratings for rigidity and tremor as well as their combination with the UPDRS-III bradykinesia rating were more sensitive a measure for progression of PD than the UPDRS-III. Conclusions: Taking into account the segmental evolution of parkinsonian signs may be a useful adjunct to UPDRS-III evaluations to measure clinical disease progression of PD. If validated in subsequent larger cohorts, this may be useful in trials of neuroprotective agents.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-3050`
A02	`01`			`@0 JNNPAU`
A03		`1`		`@0 J. neurol. neurosurg. psychiatry`
A05				`@2 81`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating`
A11	`01`	`1`		`@1 SCHÜPBACH (W. M. M.)`
A11	`02`	`1`		`@1 CORVOL (J.-C.)`
A11	`03`	`1`		`@1 CZERNECKI (V.)`
A11	`04`	`1`		`@1 DJEBARA (M. B.)`
A11	`05`	`1`		`@1 GOLMARD (J.-L.)`
A11	`06`	`1`		`@1 AGID (Y.)`
A11	`07`	`1`		`@1 HARTMANN (A.)`
A14	`01`			`@1 Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut.`
A14	`02`			`@1 INSERM, UMR 679, Neurology and Experimental Therapeutics @2 Paris @3 FRA @Z 1 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut.`
A14	`03`			`@1 AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut.`
A14	`04`			`@1 Department of Neurology, Bern University Hospital and University of Bern @3 CHE @Z 1 aut.`
A14	`05`			`@1 Service de Pharmacologie, Pitié-Salpêtrière Group @2 Paris @3 FRA @Z 2 aut.`
A14	`06`			`@1 INSERM UMR 610, Functional Neuroanatomy of Normal and Pathological Behaviour @2 Paris @3 FRA @Z 3 aut.`
A14	`07`			`@1 University Pierre et Marie Curie, Faculté de Médecine @2 Paris @3 FRA @Z 4 aut. @Z 6 aut. @Z 7 aut.`
A14	`08`			`@1 AP-HP, Pitié-Salpêtrière Group, Biostatistics Unit @2 Paris @3 FRA @Z 5 aut.`
A20				`@1 20-25`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6015 @5 354000171546500060`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 10-0032960`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of neurology, neurosurgery and psychiatry`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Objective: To assess the ability of potentially neuroprotective compounds to slow the progression of Parkinson's disease (PD), sensitive rating scales are needed to detect clinically meaningful effects. The topographical progression of motor signs in early untreated PD was evaluated to complement current clinical ratings and enhance the sensitivity to detect disease progression. Methods: 12 patients referred for diagnostic evaluation of untreated de novo PD underwent detailed clinical assessment of motor parkinsonian signs at baseline and after 6 and 12 months of follow-up using the Unified Parkinson's Disease Rating Scale, motor part (UPDRS-III), and a newly developed approach of detailed segmental rating taking into account the localisation of motor signs in all of the major joints and muscle groups in the body. The progression of PD, as measured with the UPDRS-III, was compared with the segmental ratings. Results: UPDRS-III scores and segmental ratings for rigidity and rest and postural tremor, but not bradykinesia, progressed significantly during the observation period. Progression of normalised segmental ratings for rigidity and tremor was significantly larger than the UPDRS-III ratings over 1 year. The segmental ratings for rigidity and tremor as well as their combination with the UPDRS-III bradykinesia rating were more sensitive a measure for progression of PD than the UPDRS-III. Conclusions: Taking into account the segmental evolution of parkinsonian signs may be a useful adjunct to UPDRS-III evaluations to measure clinical disease progression of PD. If validated in subsequent larger cohorts, this may be useful in trials of neuroprotective agents.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Voie abord @5 09`
C03	`03`	`X`	`ENG`	`@0 Surgical approach @5 09`
C03	`03`	`X`	`SPA`	`@0 Vía abordaje @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 018`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0032960 INIST
ET :	Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating
AU :	SCHÜPBACH (W. M. M.); CORVOL (J.-C.); CZERNECKI (V.); DJEBARA (M. B.); GOLMARD (J.-L.); AGID (Y.); HARTMANN (A.)
AF :	Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux/Paris/France (1 aut., 2 aut., 3 aut., 4 aut., 6 aut., 7 aut.); INSERM, UMR 679, Neurology and Experimental Therapeutics/Paris/France (1 aut., 4 aut., 6 aut., 7 aut.); AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut., 6 aut., 7 aut.); Department of Neurology, Bern University Hospital and University of Bern/Suisse (1 aut.); Service de Pharmacologie, Pitié-Salpêtrière Group/Paris/France (2 aut.); INSERM UMR 610, Functional Neuroanatomy of Normal and Pathological Behaviour/Paris/France (3 aut.); University Pierre et Marie Curie, Faculté de Médecine/Paris/France (4 aut., 6 aut., 7 aut.); AP-HP, Pitié-Salpêtrière Group, Biostatistics Unit/Paris/France (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 2010; Vol. 81; No. 1; Pp. 20-25; Bibl. 17 ref.
LA :	Anglais
EA :	Objective: To assess the ability of potentially neuroprotective compounds to slow the progression of Parkinson's disease (PD), sensitive rating scales are needed to detect clinically meaningful effects. The topographical progression of motor signs in early untreated PD was evaluated to complement current clinical ratings and enhance the sensitivity to detect disease progression. Methods: 12 patients referred for diagnostic evaluation of untreated de novo PD underwent detailed clinical assessment of motor parkinsonian signs at baseline and after 6 and 12 months of follow-up using the Unified Parkinson's Disease Rating Scale, motor part (UPDRS-III), and a newly developed approach of detailed segmental rating taking into account the localisation of motor signs in all of the major joints and muscle groups in the body. The progression of PD, as measured with the UPDRS-III, was compared with the segmental ratings. Results: UPDRS-III scores and segmental ratings for rigidity and rest and postural tremor, but not bradykinesia, progressed significantly during the observation period. Progression of normalised segmental ratings for rigidity and tremor was significantly larger than the UPDRS-III ratings over 1 year. The segmental ratings for rigidity and tremor as well as their combination with the UPDRS-III bradykinesia rating were more sensitive a measure for progression of PD than the UPDRS-III. Conclusions: Taking into account the segmental evolution of parkinsonian signs may be a useful adjunct to UPDRS-III evaluations to measure clinical disease progression of PD. If validated in subsequent larger cohorts, this may be useful in trials of neuroprotective agents.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Voie abord
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Surgical approach
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Vía abordaje
LO :	INIST-6015.354000171546500060
ID :	10-0032960

Links to Exploration step

Pascal:10-0032960

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating</title>
<author><name sortKey="Schupbach, W M M" sort="Schupbach, W M M" uniqKey="Schupbach W" first="W. M. M." last="Schüpbach">W. M. M. Schüpbach</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Bern University Hospital and University of Bern</s1>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corvol, J C" sort="Corvol, J C" uniqKey="Corvol J" first="J.-C." last="Corvol">J.-C. Corvol</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Service de Pharmacologie, Pitié-Salpêtrière Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Czernecki, V" sort="Czernecki, V" uniqKey="Czernecki V" first="V." last="Czernecki">V. Czernecki</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>INSERM UMR 610, Functional Neuroanatomy of Normal and Pathological Behaviour</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Djebara, M B" sort="Djebara, M B" uniqKey="Djebara M" first="M. B." last="Djebara">M. B. Djebara</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Golmard, J L" sort="Golmard, J L" uniqKey="Golmard J" first="J.-L." last="Golmard">J.-L. Golmard</name>
<affiliation><inist:fA14 i1="08"><s1>AP-HP, Pitié-Salpêtrière Group, Biostatistics Unit</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0032960</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0032960 INIST</idno>
<idno type="RBID">Pascal:10-0032960</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000624</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating</title>
<author><name sortKey="Schupbach, W M M" sort="Schupbach, W M M" uniqKey="Schupbach W" first="W. M. M." last="Schüpbach">W. M. M. Schüpbach</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Bern University Hospital and University of Bern</s1>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corvol, J C" sort="Corvol, J C" uniqKey="Corvol J" first="J.-C." last="Corvol">J.-C. Corvol</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Service de Pharmacologie, Pitié-Salpêtrière Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Czernecki, V" sort="Czernecki, V" uniqKey="Czernecki V" first="V." last="Czernecki">V. Czernecki</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>INSERM UMR 610, Functional Neuroanatomy of Normal and Pathological Behaviour</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Djebara, M B" sort="Djebara, M B" uniqKey="Djebara M" first="M. B." last="Djebara">M. B. Djebara</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Golmard, J L" sort="Golmard, J L" uniqKey="Golmard J" first="J.-L." last="Golmard">J.-L. Golmard</name>
<affiliation><inist:fA14 i1="08"><s1>AP-HP, Pitié-Salpêtrière Group, Biostatistics Unit</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title>
<title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title>
<title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title>
<idno type="ISSN">0022-3050</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Surgical approach</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Voie abord</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the ability of potentially neuroprotective compounds to slow the progression of Parkinson's disease (PD), sensitive rating scales are needed to detect clinically meaningful effects. The topographical progression of motor signs in early untreated PD was evaluated to complement current clinical ratings and enhance the sensitivity to detect disease progression. Methods: 12 patients referred for diagnostic evaluation of untreated de novo PD underwent detailed clinical assessment of motor parkinsonian signs at baseline and after 6 and 12 months of follow-up using the Unified Parkinson's Disease Rating Scale, motor part (UPDRS-III), and a newly developed approach of detailed segmental rating taking into account the localisation of motor signs in all of the major joints and muscle groups in the body. The progression of PD, as measured with the UPDRS-III, was compared with the segmental ratings. Results: UPDRS-III scores and segmental ratings for rigidity and rest and postural tremor, but not bradykinesia, progressed significantly during the observation period. Progression of normalised segmental ratings for rigidity and tremor was significantly larger than the UPDRS-III ratings over 1 year. The segmental ratings for rigidity and tremor as well as their combination with the UPDRS-III bradykinesia rating were more sensitive a measure for progression of PD than the UPDRS-III. Conclusions: Taking into account the segmental evolution of parkinsonian signs may be a useful adjunct to UPDRS-III evaluations to measure clinical disease progression of PD. If validated in subsequent larger cohorts, this may be useful in trials of neuroprotective agents.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-3050</s0>
</fA01>
<fA02 i1="01"><s0>JNNPAU</s0>
</fA02>
<fA03 i2="1"><s0>J. neurol. neurosurg. psychiatry</s0>
</fA03>
<fA05><s2>81</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHÜPBACH (W. M. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CORVOL (J.-C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CZERNECKI (V.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DJEBARA (M. B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GOLMARD (J.-L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HARTMANN (A.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Experimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Bern University Hospital and University of Bern</s1>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Service de Pharmacologie, Pitié-Salpêtrière Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>INSERM UMR 610, Functional Neuroanatomy of Normal and Pathological Behaviour</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>University Pierre et Marie Curie, Faculté de Médecine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>AP-HP, Pitié-Salpêtrière Group, Biostatistics Unit</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>20-25</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6015</s2>
<s5>354000171546500060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0032960</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of neurology, neurosurgery and psychiatry</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To assess the ability of potentially neuroprotective compounds to slow the progression of Parkinson's disease (PD), sensitive rating scales are needed to detect clinically meaningful effects. The topographical progression of motor signs in early untreated PD was evaluated to complement current clinical ratings and enhance the sensitivity to detect disease progression. Methods: 12 patients referred for diagnostic evaluation of untreated de novo PD underwent detailed clinical assessment of motor parkinsonian signs at baseline and after 6 and 12 months of follow-up using the Unified Parkinson's Disease Rating Scale, motor part (UPDRS-III), and a newly developed approach of detailed segmental rating taking into account the localisation of motor signs in all of the major joints and muscle groups in the body. The progression of PD, as measured with the UPDRS-III, was compared with the segmental ratings. Results: UPDRS-III scores and segmental ratings for rigidity and rest and postural tremor, but not bradykinesia, progressed significantly during the observation period. Progression of normalised segmental ratings for rigidity and tremor was significantly larger than the UPDRS-III ratings over 1 year. The segmental ratings for rigidity and tremor as well as their combination with the UPDRS-III bradykinesia rating were more sensitive a measure for progression of PD than the UPDRS-III. Conclusions: Taking into account the segmental evolution of parkinsonian signs may be a useful adjunct to UPDRS-III evaluations to measure clinical disease progression of PD. If validated in subsequent larger cohorts, this may be useful in trials of neuroprotective agents.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Voie abord</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Surgical approach</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vía abordaje</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>018</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0032960 INIST</NO>
<ET>Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating</ET>
<AU>SCHÜPBACH (W. M. M.); CORVOL (J.-C.); CZERNECKI (V.); DJEBARA (M. B.); GOLMARD (J.-L.); AGID (Y.); HARTMANN (A.)</AU>
<AF>Centre d'Investigation Clinique, Fédération des Maladies du Système Nerveux/Paris/France (1 aut., 2 aut., 3 aut., 4 aut., 6 aut., 7 aut.); INSERM, UMR 679, Neurology and Experimental Therapeutics/Paris/France (1 aut., 4 aut., 6 aut., 7 aut.); AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut., 6 aut., 7 aut.); Department of Neurology, Bern University Hospital and University of Bern/Suisse (1 aut.); Service de Pharmacologie, Pitié-Salpêtrière Group/Paris/France (2 aut.); INSERM UMR 610, Functional Neuroanatomy of Normal and Pathological Behaviour/Paris/France (3 aut.); University Pierre et Marie Curie, Faculté de Médecine/Paris/France (4 aut., 6 aut., 7 aut.); AP-HP, Pitié-Salpêtrière Group, Biostatistics Unit/Paris/France (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 2010; Vol. 81; No. 1; Pp. 20-25; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: To assess the ability of potentially neuroprotective compounds to slow the progression of Parkinson's disease (PD), sensitive rating scales are needed to detect clinically meaningful effects. The topographical progression of motor signs in early untreated PD was evaluated to complement current clinical ratings and enhance the sensitivity to detect disease progression. Methods: 12 patients referred for diagnostic evaluation of untreated de novo PD underwent detailed clinical assessment of motor parkinsonian signs at baseline and after 6 and 12 months of follow-up using the Unified Parkinson's Disease Rating Scale, motor part (UPDRS-III), and a newly developed approach of detailed segmental rating taking into account the localisation of motor signs in all of the major joints and muscle groups in the body. The progression of PD, as measured with the UPDRS-III, was compared with the segmental ratings. Results: UPDRS-III scores and segmental ratings for rigidity and rest and postural tremor, but not bradykinesia, progressed significantly during the observation period. Progression of normalised segmental ratings for rigidity and tremor was significantly larger than the UPDRS-III ratings over 1 year. The segmental ratings for rigidity and tremor as well as their combination with the UPDRS-III bradykinesia rating were more sensitive a measure for progression of PD than the UPDRS-III. Conclusions: Taking into account the segmental evolution of parkinsonian signs may be a useful adjunct to UPDRS-III evaluations to measure clinical disease progression of PD. If validated in subsequent larger cohorts, this may be useful in trials of neuroprotective agents.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Voie abord</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Surgical approach</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Vía abordaje</SD>
<LO>INIST-6015.354000171546500060</LO>
<ID>10-0032960</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000624 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000624 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0032960
   |texte=   Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating

Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri